In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Technical Approach to Endovascular Treatment of Patients with Ostium Lesion of Coronary Arteries

Session Poster Session 3

Speaker Associate Professor Daniil Maximkin

Congress : Heart Failure 2018

  • Topic : interventional cardiology and cardiovascular surgery
  • Sub-topic : Cardiovascular Surgery - Other
  • Session type : Poster Session
  • FP Number : P1925

Authors : Z KH Shugushev (Moscow,RU), D A Maximkin (Moscow,RU), AG Chepurnoy (Moscow,RU), OO Safonova (Moscow,RU), AV Mambetov (Moscow,RU)

Z KH Shugushev1 , D A Maximkin1 , AG Chepurnoy1 , OO Safonova1 , AV Mambetov1 , 1RUDN University - Moscow - Russian Federation ,


Aim: to increase the effectiveness of endovascular treatment in patients with ostium coronary artery lesions.

Methods: 150 patients were included in the study. Inclusion criteria: ostium atheroslerotic lesions of LAD or LCx > 70% according to QSA and IVUS; stable angina II-III functional class (CCS); silent myocardial ischemia; positive stress test. The main included 108 patients, who were randomized into 2 groups. In I group (n=54) according to IVUS, atherosclerotic plaque spread from the ostium of LAD and/or LCx to the LMCA, and in group II (n = 54) - the plaque did not spread into the LMCA. In Group I all patients were initially treated with «Provisional T» stenting of the LMCA, and in Group II - stenting of the ostium LAD or LCx. In retrospectively, the third (III) control group (n=42) was formed, where the stenting of the ostium of LAD or LCx was performed without IVUS. Drug-eluting stents were implanted in all patients. Long-term results were evaluated on average over a period of 30.04±12.04 months in 50 patients from group I, in 48 patients from group II and in 40 - from group III. Primary endpoints: frequency of MACE (death, MI, revascularizations). Secondary endpoints: frequency of restenosis and late stent thrombosis according to QSA and IVUS.

Results: during hospitalization of complications associated with PCI was not, survival was 100% in all groups. There was no conversion to complete bifurcation stenting. Survival in the long-term period was 100% in all groups. In all patients, in comparison with preoperative data, tolerance to physical activity significantly increased. Nonfatal MI was observed in 7.5% of patients from group III (p <0.05), in the I and II group of cases MI was not recorded. The incidence of stent restenosis and target lesion revascularization (TLR) according to QSA and IVUS was observed in 1 patient (2%) in group I, in 1 patient (2.1%) in group II and in 4 patients (10%) in III group (p<0.05). Frequency of target vessel revascularization (TVR) occurred in group I in 2% of patients, in group II in 2.1%, and in group III in 7.5% (p<0.05). The total frequency of MACE in groups I, II and III was 2; 2.1 and 25%, respectively (p <0.05). Among patients in group III, 1 case of stent thrombosis (2.5%) was verified 12 months after PCI.
Conclusion: the use of IVUS for the analysis of the ostium lesions of coronary artery allows us to choose the optimal stenting technique and also reliably improve the long-term results of endovascular intervention by reducing the incidence of stent restenosis and MACE.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are